4 October 2023 - NICE has recommended evidence based recommendations on the use of bimekizumab (Bimzelx) for the treatment of adults with active psoriatic arthritis.

Bimekizumab, when used as monotherapy or in combination with methotrexate, is recommended as an option for the treatment of adults with active psoriatic arthritis (defined as peripheral arthritis with 3 or more tender joints and 3 or more swollen joints) whose condition has not responded well enough to disease-modifying anti-rheumatic drugs or who cannot tolerate them.

Read NICE technology appraisal guidance